Boston Children’s Hospital

Recognized as Center of Excellence on 9/16/2017

Public Announcement

Phone: (617) 919-1379

Address: 300 Longwood Ave, Boston MA 02115

Number of CCM outpatient appointments annually: ~50

Number of CCM inpatient days annually: ~110

Number of CCM research publications 2012-2017: 17

Patients may also be seen at Boston Children’s at Waltham, Boston Children’s at Peabody, and Boston Children’s at Dartmouth.

Faculty

Medical Director and Pediatric Cerebrovascular Neurosurgeon: Edward Smith, MD

Pediatric Neurologist: Michael Rivkin, MD,  Laura Lehman. MD

Pediatric Epileptologist: Phillip Pearl, MD

Geneticist: Siddharth Srivastava, MD

Neurointerventional Radiologist: Darren Orbach, MD

Researcher: Mustafa Sahin, MD, Ph.D.

Nurse Coordinator: Jennifer Klein, MSN-FNP

Summary of Boston Children’s Hospital Research Program

Boston Children’s Hospital has been actively engaged in clinical and translational research related to cavernous malformations.  The hospital encompasses the Vascular Biology Program (VBP), headed by Dr. Marsha Moses, one of the largest basic and translational research programs in the world focused on vascular disease. There are ongoing protocols for patient-derived cell lines for therapeutic targeting (DFCI 10-417), small molecule drug delivery targeting and urinary biomarker screening (AS 10-076-7) translational work.  There are numerous basic studies, primarily done in the VBP looking at endothelial cell biology and migration.

The Brain Vascular Malformations Consortium is a multi-center, multi-disease research study aimed at investigating the clinical variability of three rare brain blood vessel diseases, Sturge Weber Syndrome (SWS), Hereditary Hemorrhagic Telangiectasia (HHT), and Cerebral Cavernous Malformations (CCM). Dr. Smith’s group at BCH has recently joined the CCM Study team as a research partner and recruitment site. Adult and pediatric patients with multiple lesions and family history, or with positive genetic testing for mutation in CCM1, CCM2, or CCM3 may enroll in the study. To help researchers understand better the natural variability of CCM disease, participants agree to share their medical and imaging history with the study team and to be contacted each year for five years for followup questioning. Study participants also provide a blood and/or saliva sample for genetic analysis and a stool sample for microbiome analysis.

Lastly, there are several ongoing clinical studies, including a long-term follow-up and outcomes study (CR 127-54-2) for pediatric cavernous malformations.

Patient Education/Support

Includes a dedicated web page for CCM, a nurse hotline, and patient lectures at BCH in Boston.

Medical Provider Education

Includes Grand Rounds and incorporation of CCM in medical school training.